Bayer antibiotics spin-out Aicuris bags IM...The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching … more ➔
Tiziana joins rheumatoid arthritis raceThe London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune. more ➔
Sanofi and Boehringer Ingelheim close ?bus...French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheims consumer healthcare (CHC) business in exchange for Sanofis animal health … more ➔
Best of 2016: Our most wanted newsWhich European Biotechnology news stories topped the charts this year? The European Biotechnology team delved into archives and analysed the click statistics. And here they are: the most wanted news … more ➔
Blood test on the scent of prionsContaminated blood can transmit prion disease even if the donor does not yet show any symptoms. A new blood test could make the blood supply safer. Two reports show it can correctly diagnose Variant … more ➔
IMI launches €348m callElectronic submission systems of the Innovative Medicines Initiative (IMI) will open for biotech companies and research groups on 4 January 2017 to apply for collaborative projects with pharma partners … more ➔
Belgian spin-off Indigo challenges diabete... Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The companys needle-free glucose sensor addresses … more ➔
EMA recommends market approval of four bio... The Europan Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted … more ➔
Evotec bags US$45m upfront in Celgene dealNeurology specialist Celgene has nailed down access to Evotecs induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases. more ➔
Grifols confirms €1.75bn acquisition in...Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit. more ➔
